RT Journal Article
SR Electronic
T1 Anagliptin monotherapy in patients with type 2 diabetes mellitus and high low-density lipoprotein cholesterol reduces fasting plasma lathosterol level: a single-arm intervention trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.16.20095307
DO 10.1101/2020.05.16.20095307
A1 Ikegami, Yuichi
A1 Inoue, Ikuo
A1 Takenaka, Yasuhiro
A1 Saito, Daigo
A1 Noda, Mitsuhiko
A1 Shimada, Akira
YR 2020
UL http://medrxiv.org/content/early/2020/05/22/2020.05.16.20095307.abstract
AB Background Anagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, has been shown to decrease low-density lipoprotein cholesterol (LDL-C) levels in plasma.Aim of study The objective of our study is to elucidate the mechanisms responsible for anagliptin-mediated improvements in high LDL-C levels (hyper-LDL-C-emia).Methods We prospectively examined the effects of anagliptin monotherapy on fasting plasma lathosterol, sitosterol, and campesterol levels in patients with type 2 diabetes mellitus and hyper-LDL-C-emia for 6 months. We examined 8 patients who did not use hypoglycemic or lipid-lowering drugs, other than anagliptin, for 4 months before initiating the study. Serum variables related to glucose and lipid metabolism were measured before and after the treatment for 6 months and pre- and post-prandially using the cookie-loading test.Results After treatment, anagliptin monotherapy (n = 8) significantly decreased fasting LDL-C (182.8 to 167.8 mg/dL, as mean values of before and after the treatment) and plasma lathosterol levels (3.2 to 2.6 mg/dL); however, no significant changes were observed in fasting sitosterol or campesterol levels. Furthermore, a significant increase (p = 0.0012) in the change in 1-h post-prandial active glucagon-like peptide-1 (GLP-1) levels was observed after anagliptin treatment. For all participants (n = 17), fasting plasma lathosterol levels were negatively correlated with pre-prandial GLP-1 levels.Conclusion Anagliptin monotherapy may have a beneficial effect on lipid metabolism, which is mediated by the inhibition of hepatic cholesterol synthesis, and not by the inhibition of intestinal lipid transport.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialUMIN000011256Clinical Protocols https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013194 Funding StatementThis work was supported by an annual budget of Department of Endocrinology and Diabetes, Saitama Medical University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.